title: Clinical investigation on the hypolipidemic effect of simvastatin in primary hypercholesterolemia.
abstract: Simvastatin, 20 mg daily, was given orally to 21 hypercholesterolemic outpatients for 16 weeks. During treatment a significant reduction was found in plasma total and LDL cholesterol; plasma HDL-cholesterol levels increased during the treatment. Results indicate that simvastatin, because of its activity and lack of toxicity and side effects, can be considered a drug of first-choice for the treatment of primary hypercholesterolemia.
authors.affiliation: Department of Medicine, USL 7 Val di Nievole, Pescia.
authors.forename: P
authors.initials: P
authors.lastname: Saba
authors.forename: F
authors.initials: F
authors.lastname: Galeone
authors.forename: F
authors.initials: F
authors.lastname: Giuntoli
authors.forename: G
authors.initials: G
authors.lastname: Spagnolo
authors.forename: G
authors.initials: G
authors.lastname: Brunelleschi
authors.forename: F
authors.initials: F
authors.lastname: Lamanna
authors.forename: B
authors.initials: B
authors.lastname: Angelé
mesh_terms: D000924:Anticholesteremic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002214:Capsules; D004341:Drug Evaluation; D005215:Fasting / Q000097:blood; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019821:Simvastatin; D013997:Time Factors
chemical_list: D000924:Anticholesteremic Agents; D002214:Capsules; D008055:Lipids; D008148:Lovastatin; D019821:Simvastatin